Citadel Advisors
TEVA icon

Citadel Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Citadel Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.4M Sell
1,275,500
-1,213,400
-49% -$39M 0.01% 1602
2025
Q4 		$77.7M Buy
2,488,900
+320,700
+15% +$7.9M 0.01% 1042
2025
Q3 		$43.8M Sell
2,168,200
-461,700
-18% -$8.11M 0.01% 1523
2025
Q2 		$44.1M Sell
2,629,900
-809,600
-24% -$13.1M 0.01% 1335
2025
Q1 		$52.9M Sell
3,439,500
-885,900
-20% -$15.8M 0.01% 1096
2024
Q4 		$95.3M Buy
4,325,400
+3,800,300
+724% +$69.1M 0.02% 758
2024
Q3 		$9.46M Sell
525,100
-64,500
-11% -$1.13M ﹤0.01% 2985
2024
Q2 		$9.58M Sell
589,600
-853,800
-59% -$13.2M ﹤0.01% 2821
2024
Q1 		$20.4M Buy
1,443,400
+341,400
+31% +$4.3M ﹤0.01% 2042
2023
Q4 		$11.5M Sell
1,102,000
-492,300
-31% -$4.6M ﹤0.01% 2655
2023
Q3 		$16.3M Sell
1,594,300
-230,300
-13% -$2.14M ﹤0.01% 2099
2023
Q2 		$13.7M Sell
1,824,600
-448,100
-20% -$3.63M ﹤0.01% 2281
2023
Q1 		$20.1M Sell
2,272,700
-1,849,800
-45% -$18.3M ﹤0.01% 1910
2022
Q4 		$37.6M Buy
4,122,500
+529,000
+15% +$4.62M 0.01% 1354
2022
Q3 		$29M Sell
3,593,500
-914,400
-20% -$8.09M 0.01% 1507
2022
Q2 		$33.9M Buy
4,507,900
+1,315,400
+41% +$11.5M 0.01% 1363
2022
Q1 		$30M Sell
3,192,500
-2,800
-0.1% -$23.4K 0.01% 1553
2021
Q4 		$25.6M Sell
3,195,300
-1,077,800
-25% -$9.73M 0.01% 1754
2021
Q3 		$41.6M Buy
4,273,100
+1,237,300
+41% +$11.6M 0.01% 1276
2021
Q2 		$30.1M Buy
3,035,800
+1,272,300
+72% +$13.5M 0.01% 1612
2021
Q1 		$20.4M Sell
1,763,500
-623,400
-26% -$7.15M 0.01% 1939
2020
Q4 		$23M Buy
2,386,900
+219,700
+10% +$2.1M 0.01% 1654
2020
Q3 		$19.5M Buy
2,167,200
+561,300
+35% +$5.94M 0.01% 1598
2020
Q2 		$19.8M Sell
1,605,900
-965,000
-38% -$10.9M 0.01% 1507
2020
Q1 		$23.1M Sell
2,570,900
-360,000
-12% -$3.69M 0.01% 1122
2019
Q4 		$28.7M Sell
2,930,900
-135,800
-4% -$1.21M 0.01% 1160
2019
Q3 		$21.1M Buy
3,066,700
+803,200
+35% +$6.15M 0.01% 1422
2019
Q2 		$20.9M Buy
2,263,500
+569,700
+34% +$6.87M 0.01% 1380
2019
Q1 		$26.6M Sell
1,693,800
-635,500
-27% -$11.2M 0.01% 1104
2018
Q4 		$35.9M Buy
2,329,300
+271,600
+13% +$5.57M 0.02% 807
2018
Q3 		$44.3M Sell
2,057,700
-26,700
-1% -$620K 0.02% 831
2018
Q2 		$50.7M Sell
2,084,400
-533,500
-20% -$10.9M 0.02% 698
2018
Q1 		$44.7M Buy
2,617,900
+1,044,800
+66% +$20.4M 0.02% 652
2017
Q4 		$29.8M Sell
1,573,100
-420,300
-21% -$6.32M 0.02% 917
2017
Q3 		$35.1M Buy
1,993,400
+1,227,900
+160% +$27.6M 0.03% 733
2017
Q2 		$25.4M Sell
765,500
-183,300
-19% -$5.67M 0.02% 846
2017
Q1 		$30.4M Sell
948,800
-224,500
-19% -$7.66M 0.03% 701
2016
Q4 		$42.5M Buy
1,173,300
+608,100
+108% +$24.3M 0.04% 449
2016
Q3 		$26M Buy
565,200
+96,800
+21% +$5.05M 0.03% 719
2016
Q2 		$23.5M Buy
+468,400
New +$24.9M 0.03% 666

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's TEVA Position: Q1 2026 in Review

Citadel Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 3,847,855 shares — an estimated $124M sold.

Citadel Advisors first reported a position in TEVA in Q2 2013 and held it in 51 quarters. The position peaked at $121M in Q4 2023. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Citadel Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 3,847,855 Teva Pharmaceuticals shares in Q1 2026, an estimated $124M.
  • Citadel Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 51 quarters.
  • Citadel Advisors's Teva Pharmaceuticals position peaked at $121M in Q4 2023.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.